← Leaderboards
Scott Q Harper
Research Inst Nationwide Children'S Hosp
$9,530,406
Attributed
$10,416,433
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,416,433 · 12
By mechanism
R01$4,506,920 · 2
R21$2,505,066 · 6
P50$1,773,543 · 2
R61$841,280 · 1
R33$789,624 · 1
Top collaborators
- Robert W Burgess4 shared
- James J Dowling2 shared
Most similar at Research Inst Nationwide Children'S Hosp
Same institution · by research overlap
- Kevin M Flanigan$19,837,604
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesAffectMuscleGene TherapyMuscular DystrophiesIn VivoFacioscapulohumeral Muscular DystrophyOverexpressionPathogenesisTranscription FactorDesignTranslationsPhenotypeEffective TherapyLengthMouse ModelMyopathyEventRna InterferenceEngineeringIn VitroPreventAdeno-Associated Viral VectorPrograms
Grant awards (32)
CRISPR-Cas13 gene therapy and RNA editing for Facioscapulohumeral muscular dystrophy (FSHD)$501,784
R01 · FY2025 · AR · contact PI
tRNA Gene Replacement Therapy for tRNA-Synthetase Related Charcot-Marie-Tooth Disorder$411,015
R61 · FY2025 · NS
MDSRC Training Core$141,068
P50 · FY2025 · HD · contact PI
CRISPR-Cas13 gene therapy and RNA editing for Facioscapulohumeral muscular dystrophy (FSHD)$540,811
R01 · FY2024 · AR · contact PI
tRNA Gene Replacement Therapy for tRNA-Synthetase Related Charcot-Marie-Tooth Disorder$430,265
R61 · FY2024 · NS
MDSRC Training Core$148,896
P50 · FY2024 · HD · contact PI
AAV mediated gene knockdown of PIK3C2B as a therapeutic strategy for X-linked myotubular myopathy and fatty liver disease$125,479
R21 · FY2024 · AR · contact PI
CRISPR-Cas13 gene therapy and RNA editing for Facioscapulohumeral muscular dystrophy (FSHD)$620,756
R01 · FY2023 · AR · contact PI
AAV mediated gene knockdown of PIK3C2B as a therapeutic strategy for X-linked myotubular myopathy and fatty liver disease$196,642
R21 · FY2023 · AR · contact PI
CRISPR-Cas13 gene therapy and RNA editing for Facioscapulohumeral muscular dystrophy (FSHD)$607,917
R01 · FY2022 · AR · contact PI
Chromatin remodeling gene therapy for FSHD using split-vector AAV SMCHD1 vectors$177,264
R21 · FY2022 · AR · contact PI
CRISPR-Cas13 gene therapy and RNA editing for Facioscapulohumeral muscular dystrophy (FSHD)$624,920
R01 · FY2021 · AR · contact PI
Chromatin remodeling gene therapy for FSHD using split-vector AAV SMCHD1 vectors$217,960
R21 · FY2021 · AR · contact PI
In vivo efficacy studies to support the development of DUX4-targeted RNAi therapy for FSHD$388,410
R33 · FY2020 · NS · contact PI
Project 2: DUX4 inhibition with non-coding RNAs as a therapeutic strategy for facioscapulohumeral muscular dystrophy (FSHD)$282,063
P50 · FY2020 · AR · contact PI
In vivo efficacy studies to support the development of DUX4-targeted RNAi therapy for FSHD$401,214
R33 · FY2019 · NS · contact PI
Gene Therapy Knockdown and Replacement of GARS to Treat Dominant Inherited Peripheral Neuropathy$318,345
R21 · FY2019 · NS
Project 2: DUX4 inhibition with non-coding RNAs as a therapeutic strategy for facioscapulohumeral muscular dystrophy (FSHD)$273,942
P50 · FY2019 · AR · contact PI
Gene Therapy Knockdown and Replacement of GARS to Treat Dominant Inherited Peripheral Neuropathy$290,309
R21 · FY2018 · NS
Project 2: DUX4 inhibition with non-coding RNAs as a therapeutic strategy for facioscapulohumeral muscular dystrophy (FSHD)$284,503
P50 · FY2018 · AR · contact PI
In vivo efficacy studies to support the development of DUX4-targeted RNAi therapy for FSHD$389,002
R21 · FY2017 · NS · contact PI
Project 2: DUX4 inhibition with non-coding RNAs as a therapeutic strategy for facioscapulohumeral muscular dystrophy (FSHD)$343,081
P50 · FY2017 · AR · contact PI
DUX4 and the P53 pathway in FSHD pathogenesis$327,375
R01 · FY2016 · AR · contact PI
Project 2: DUX4 inhibition with non-coding RNAs as a therapeutic strategy for facioscapulohumeral muscular dystrophy (FSHD)$299,990
P50 · FY2016 · AR · contact PI
DUX4 and the P53 pathway in FSHD pathogenesis$327,375
R01 · FY2015 · AR · contact PI
DUX4 and the P53 pathway in FSHD pathogenesis$320,828
R01 · FY2014 · AR · contact PI
DUX4 and the P53 pathway in FSHD pathogenesis$311,006
R01 · FY2013 · AR · contact PI
DUX4 inhibition as a therapeutic strategy for FSHD$174,665
R21 · FY2013 · NS · contact PI
DUX4 and the P53 pathway in FSHD pathogenesis$324,148
R01 · FY2012 · AR · contact PI
RNAi Therapy for Dominant Limb Girdle Muscular Dystrophy Type 1A$217,200
R21 · FY2012 · NS · contact PI
DUX4 inhibition as a therapeutic strategy for FSHD$217,200
R21 · FY2012 · NS · contact PI
RNAi Therapy for Dominant Limb Girdle Muscular Dystrophy Type 1A$181,000
R21 · FY2011 · NS · contact PI